Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 5/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.49 |
| ▸ | PDE2A | O00408 | 3/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024719 | 0.90 | PIK3CA (0.53) | BCDIN3DPIK3CAPDE2ATP53 | |
| SCHEMBL31337009 | 0.78 | MEN1 (0.55) | BCDIN3DPDE2AHTR2CHTTTP53 | |
| SCHEMBL23598948 | 0.78 | MEN1 (0.55) | BCDIN3DPDE2AHTR2CHTTTP53 | |
| SCHEMBL22025542 | 0.77 | EPHB4 (0.59) | BCDIN3DIRAK1IRAK4 | |
| SCHEMBL22024565 | 0.77 | KDR (0.53) | BCDIN3DPIK3CAPDE2AIRAK1IRAK4 | |
| SCHEMBL22024568 | 0.77 | KDR (0.53) | BCDIN3DPIK3CAPDE2AIRAK1IRAK4 | |
| SCHEMBL23598914 | 0.77 | MEN1 (0.67) | BCDIN3DPIK3CAPDE2AHTR2CTP53 | |
| SCHEMBL23598947 | 0.77 | PDE2A (0.49) | BCDIN3DPDE2AHTR2CTP53 | |
| SCHEMBL23579808 | 0.75 | MEN1 (0.51) | BCDIN3DPIK3CAPDE2ATP53 | |
| SCHEMBL30033670 | 0.75 | MEN1 (0.51) | BCDIN3DPIK3CAPDE2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | BCDIN3D 2763/4885PIK3CA 2/4885PDE2A 2848/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | BCDIN3D 2763/4885PIK3CA 2/4885PDE2A 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.